Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Ethnopharmacol ; 260: 112972, 2020 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-32446928

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Fagara tessmannii is a shrub of the African rainforests in South-West, Centre, South and East provinces in Cameroon. It is used in traditional medicine for the treatment of tumors, swellings, inflammation, gonorrhoea, schistosomiasis, antifungal, heart diseases and as anti-hypertensive. AIM OF THE STUDY: We investigated the potential effects of F. tessmannii on cardiovascular risk related to monosodium glutamate-induced obesity. MATERIALS AND METHODS: Monosodium glutamate (MSG, 4 mg/g/day) was injected subcutaneously to newborn Wistar rats for the four consecutive first days of their life and on the 6th, 8th and 10th day after birth. After 21 weeks, obese rats were treated orally with F. tessmannii (100 or 200 mg/kg/day), orlistat (10 mg/kg/day) or telmisartan (10 mg/kg/day) for 6 weeks. Body weight, obesity, body mass index (BMI), Lee index, insulin sensitivity and glucose tolerance, blood pressure, lipid profile as a Coronary Risk Index (CRI), and reactivity of isolated thoracic aorta were evaluated. RESULTS: In addition to significantly decrease body weight (17.60% and 20.34%), BMI, Lee's index, retroperitoneal fat, total adiposity, and coronary risk indicators, F. tessmannii has significantly decreased insulin resistance and hyperglycemia and high blood pressure observed in MSG-obese rats. The high contractility to phenylephrine as well as the hypersensitivity to sodium nitroprusside (a nitric oxide-donor), observed in MSG aortic rings were significantly reduced by the F. tessmannii extract. Enhanced serum Na+ and Cl- levels and decreased K+ observed in obese rats were also significantly reversed after F. tessmannii treatment. CONCLUSIONS: F. tessmannii fights against obesity and associated cardiovascular risks by modulating production and vascular responsiveness to vasoactive factors, monitoring premature aging. F. tessmannii promotes the loss of ectopic fat and other fatty tissues, the sensitivity of the peripherical tissues to insulin, the energy expenditure and the renovascular decompression and regulates ions movement which prevents hypertension.


Assuntos
Fármacos Antiobesidade/farmacologia , Hemodinâmica/efeitos dos fármacos , Hipertensão/prevenção & controle , Obesidade/tratamento farmacológico , Casca de Planta , Extratos Vegetais/farmacologia , Caules de Planta , Zanthoxylum , Adiposidade/efeitos dos fármacos , Animais , Animais Recém-Nascidos , Fármacos Antiobesidade/isolamento & purificação , Pressão Arterial/efeitos dos fármacos , Biomarcadores/sangue , Índice de Massa Corporal , Modelos Animais de Doenças , Feminino , Hipertensão/etiologia , Hipertensão/fisiopatologia , Resistência à Insulina , Masculino , Obesidade/sangue , Obesidade/induzido quimicamente , Obesidade/fisiopatologia , Casca de Planta/química , Extratos Vegetais/isolamento & purificação , Caules de Planta/química , Ratos Wistar , Medição de Risco , Fatores de Risco , Glutamato de Sódio , Vasoconstrição/efeitos dos fármacos , Redução de Peso/efeitos dos fármacos , Zanthoxylum/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA